Abstract
The JAK2V617F mutation is an activating kinase that is constitutively expressed in the vast majority of patients with polycythemia vera and approximately half of those with essential thrombocythemia (ET).1 The significance of the association between JAK2V617F mutation in ET and thrombosis is still controversial: we have shown that ET patients with JAK2V617F had more frequent thrombotic episodes compared with those with wild-type JAK2, whereas the platelet count at the initial ET diagnosis did not differ between wild-type ET and JAK2V617F-positive ET.2 On the basis of this evidence, we retrospectively sought and evaluated thrombotic episodes in ET patients to obtain more insight into the risk factors of thrombosis in ET patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
